Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|August 28, 2020
- Pharmaceutical Technology's In the Lab eNewsletter 09-02-2020
- Volume 15
- Issue 9
Eppendorf Launches Move It Adjustable Spacing Pipettes for Synchronous Pipetting
Author(s)Pharmaceutical Technology Editors
Move It Adjustable Spacing Pipettes are a simple and safe solution for synchronous pipetting of a series of samples between different vessel formats.
Advertisement
Eppendorf introduced Move It Adjustable Spacing Pipettes for a simple and safe solution for synchronous pipetting of a series of samples between different vessel formats. Without tubing connections between the cone and piston-cylinder system, Move It reduces operating time and increases precision and durability without the need for several moving, fragile parts. Additionally, autoclavability is enabled, which escalates user and sample-safety.
"Our product engineers have developed a special design concept for a well-balanced and ergonomic pipette," said Peter Schmidt, business manager, Eppendorf, in an Aug. 12, 2020 company press release. "Further, the manual adjustment of the tip distance with the adjustment knob makes it possible to maintain this relaxed-ergonomic hand position even during format change.”
Source:
Articles in this issue
about 6 years ago
Outlining Drug Stability and Solubility with Dissolution Testingabout 6 years ago
Dotmatics Launches Bioregister 2020.1about 6 years ago
Thermo Fisher and CROs Expand Access to Cryo-EMabout 6 years ago
Lonza Expands its Microbial Manufacturing Facility in Switzerlandabout 6 years ago
PPD and Pfizer Enter into Three-Year AgreementAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5